NCT05085002 is a Phase 2 clinical trial of Lerociclib + Letrozole or Fulvestrant in Advanced Breast Cancer, sponsored by EQRx, Inc..

Who is sponsoring NCT05085002?

NCT05085002 is sponsored by EQRx, Inc..

What drugs are being tested in NCT05085002?

Interventions in NCT05085002: Lerociclib + Letrozole or Fulvestrant.

What condition does NCT05085002 study?

NCT05085002 studies Advanced Breast Cancer.

Is NCT05085002 still recruiting?

NCT05085002 is currently terminated. Last updated 12 March 2024.

Are results published for NCT05085002?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-03-12 · How we verify

NCT05085002

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Lerociclib in Participants With Advanced Breast Cancer

Terminated Phase 2 Results posted Last updated 12 March 2024

What this trial tests

Phase 2 trial testing Lerociclib + Letrozole or Fulvestrant in Advanced Breast Cancer in 100 participants. Terminated before completion.

Timeline

21 December 2021

Primary endpoint
29 November 2023

29 November 2023

Quick facts

Lead sponsor	EQRx, Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	21 December 2021
Primary completion	29 November 2023
Estimated completion	29 November 2023
Sites	21 locations across Moldova, Belgium, United States, Italy, Georgia, Mexico

Drugs / interventions tested

Lerociclib + Letrozole or Fulvestrant — full drug profile →

Conditions studied

Advanced Breast Cancer — all drugs for Advanced Breast Cancer →

Sponsor

EQRx, Inc. — full company profile →

Who can join

18 and older, any sex, with Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, single-arm, open-label study to evaluate the safety and efficacy of lerociclib in combination with standard endocrine therapy in female or male participants with HR+/HER2- MBC. The study population will consist of either newly diagnosed, treatment naïve participants with HR+/HER2- MBC (1L population) and participants with HR+/HER2- MBC who have already progressed on first line endocrine therapy such as tamoxifen, anastrozole, or letrozole (2L population). All premenopausal or perimenopausal female participants, and all male participants, must be receiving goserelin for at least 28 days prior to entering the study and will remain on goserelin throughout the study, in accordance with the prescribing information and according to the study site's standard practice.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Small molecule inhibitors targeting the cancers.
Liu GH, Chen T, Zhang X, Ma XL, et al · · 2022 · cited 127× · PMID 36254250 · DOI 10.1002/mco2.181
Role of HOXA9 in solid tumors: mechanistic insights and therapeutic potential.
Tang L, Peng L, Tan C, Liu H, et al · · 2022 · cited 19× · PMID 36376832 · DOI 10.1186/s12935-022-02767-9

Verify or expand the search:

Other recruiting trials for Advanced Breast Cancer

Currently open trials in the same condition.

NCT07408089 — Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer · Phase 1 · recruiting
NCT07318805 — A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
NCT07259226 — Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers · Phase 2 · recruiting
NCT06982521 — Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PI · Phase 3 · recruiting
NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting

Other EQRx, Inc. trials

Trials by the same sponsor.

NCT04969965 — To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05085002 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by EQRx, Inc.
Last refreshed: 12 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05085002.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing